Although pigmented basal cell carcinoma (PBCC) in individuals with darker skin color has been well described in dermatologic literature, it is recognized as a rare condition in the general population, and has rarely been reported specifi cally to the eyelid region (Duke-Elder and MacFaul 1974; Charles 1975 ). Since PBCC is not commonly considered in the differential diagnosis by general ophthalmologists for eyelid lesions, it is often mistaken for melanoma (Scotto et al 1983) . Indeed, some features of PBCC lesions, such as its irregular borders and dark pigment, are suggestive of melanoma (Pathak et al 1982) . Reports of frequency vary. The frequency for all sites ranges from 1.1% to 8% (Bart and Schnall 1973) . In one series that investigated the eyelid site only, 9% of all diagnosed basal cell carcinomas in a population of white patients were found to be PBCC (Hornblass and Stefano 1981) .
Although Hispanic patients get skin cancer signifi cantly less frequently than nonHispanic individuals (Pathak et al 1982; Harris et al 2001) , PBCC of all sites has been shown to occur more frequently in Hispanics than in non-Hispanics (Bigler et al 1996) . We have seen PBCC of the eyelid occurring with common frequency in our Hispanic patients. Our case series describes four of eight Hispanic patients who presented with primary eyelid malignant lesions that were proven on biopsy to be PBCC.
Materials and methods
Clinical medical records for patients seen between January 2002 and November 2005 by the Mohs surgery division of the Department of Dermatology at the Keck School of Medicine of the University of Southern California were reviewed retrospectively. Seventy-nine consecutive cases of primary eyelid skin cancer were found. Cases of eyelid basal cell carcinoma in patients of Hispanic descent were identifi ed and studied. Hispanic descent was determined by heritage documentation based on questions asked of every patient admitted for Mohs surgery. The records were reviewed for patient history, presentation, lesion size, number of Mohs stages for excision, and defect size. The clinical records of these same patients from the Department of Oculoplastics and Reconstructive Surgery at Doheny Eye Institute were also reviewed. The records were reviewed for patient history, presentation, lesion duration and appearance, type of closure needed for reconstruction, and recurrence. No patient had previous treatment or biopsies prior to Mohs excision. The histopathological slides were read at the time of Mohs excision by the dermatopathologist. The study protocol was approved by the University of Southern California Institutional Review Board.
Results
Sixty-nine of 79 eyelid skin cancer cases were found to have basal cell carcinoma. Of these 69 patients, 8 were of Hispanic descent. Four of these patients had PBCC. Representative clinical photographs are seen in Figure 1 (Case 1) and Figure 2 (Case 4). All four patients were male, with a mean age of 63 years (range 57 to 75 years). Lesion duration ranged from 7 months to 6 years. None of these patients had lymphadenopathy. Two patients felt the lesion was secondary to minor trauma. All patients were treated with Mohs excision. No patient has experienced recurrence. There were no cases of neural or perineural involvement. Table 1 summarizes the fi ndings for all four patients.
Discussion
A 2001 report (Harris et al 2001) on trends in the incidence of nonmelanoma skin cancers in southeastern Arizona found that non-Hispanic whites were 11 times more likely than Hispanics to develop either basal or squamous cell carcinoma. Similarly, a 1982 report on the incidence of basal cell carcinoma and melanoma in New Mexico found that these cancers occurred seven times less often in Hispanics than in non-Hispanics (Pathak et al 1982) .
Although both basal and squamous cell carcinoma, as well as melanoma, occur with less frequency in the Hispanic population than in the non-Hispanic population, it has been shown that PBCC occurs more often in Hispanics. In one prospective series (Bigler et al 1996) , for BCC at any site, 66% of all BCCs in Hispanics were found to be PBCC, whereas only 11% of all BCCs in non-Hispanic patients were PBCC. Pigmented basal cell carcinoma has also been shown to occur with higher frequency in patients with darker skin color (Smith et al 1960; Kalter et al 1984; Abreo and Sanusi 1991) .
Histologic studies have shown that the pigment in PBCC originates from the surrounding skin (Bleehan 1975) . Hornblass and Stefano (1981) described pigmented basal cell carcinoma specifi c to the eyelid in white patients. Haye and Dufi er (1976) reported a relative frequency of 1% for PBCC of the eyelid in the population in Paris, which increased to 45% in Mediterranean ethnic groups. After careful review of the literature, to the best of the authors' knowledge, eyelid PBCC specifi c to the Hispanic population has not been reported. Just as eyelid PBCC is more frequent in the darker skinned Mediterranean population, it is likely that PBCC of the eyelid also occurs more commonly in Hispanics than in non-Hispanics.
Because PBCC is not commonly considered in the differential of eyelid pigmented lesions of general ophthalmologists, these lesions are often misdiagnosed as melanoma. Both lesions can have irregular borders and dark pigment. However, some features of PBCC can help differentiate it from Eyelid pigmented BCC in hispanics melanoma. Pigmented basal cell carcinoma is more likely to have mottled appearance since the pigment is often located superfi cially in the dermis (Bigler et al 1996) . Melanoma, on the other hand, tends to have intense or masking pigment (Haye and Dufi er 1976) . Other features that help differentiate PBCC from melanoma include a translucent or pearly sheen, fi rm or indurated lesions, areas of ulceration, and raised edges (Hornblass and Stefano 1981; Bigler et al 1996) .
Clinicians should be aware that PBCC of the eyelid occurs more frequently in Hispanics, a population less frequently affected by other skin carcinomas, and consider PBCC on their differential diagnosis of all pigmented eyelid lesions.
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